Imaging of the bacterial interactions in lung co-infection in cystic fibrosis patients | CMAC

Imaging of the bacterial interactions in lung co-infection in cystic fibrosis patients

Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(2):155-160

​ Burkaltseva M.V., Lazareva A.V., Pleteneva E.A., Shaburova O.V., Krylov S.V., Mikhailova N.A., Poddubikov A.V., Lazarev S.A., Zverev V.V., Krylov V.N.
10.36488/cmac.2020.2.155-160
cystic fibrosis co-infection bacterial interactions Pseudomonas aeruginosa Alcaligenes faecalis
Section
Personal Experience
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(2):155-160

Objective.

To identify bacterial interactions at the site of infection in cystic fibrosis patients and to assess their possible effects on the course of infection.

Materials and Methods.

The following strains were used in this study: Alcaligenes faecalis LGBP strain, isolated from the environment; clinical isolates of Pseudomonas aeruginosa; Achromobacter xylosoxidans, Acinetobacter baumannii, Alcaligenes faecalis, and Bacillus subtilis strains; the standard laboratory P. aeruginosa PAO1 strain and its lysogens by temperate bacteriophages of various species, and its phageresistant mutants. Imaging and evaluation of the effects of bacterial interaction was performed in an in vitro co-infection with A. faecalis LGBP and the tested strains.

Results.

The bacteria of A. faecalis which are often involved in the lung co-infection in cystic fibrosis have been shown to stimulate the growth of most of the tested P. aeruginosa strains, as well as bacteria of some other species (for example, B. subtilis). The interspecies interactions pattern depends primarily on the strain of A. faecalis and physiological features of the infecting P. aeruginosa strains. When growing concurrently, the contacts between bacteria may change both the physical properties of the contacting bacteria surface (propagation rate) and the course of biochemical reactions in the contacting bacteria (occurrence of pigmentation, change in auto-plaquing pattern, reduction in alginate production).

Conclusions.

The results suggest that visually recognizable interactions are similar to the interactions of A. faecalis LGBP, exhibited in vitro with clinical isolates of P. aeruginosa, may influence on the course of chronic infections and their treatment results. Expanding of model studies of bacterial interspecies interactions may contribute to better understanding of their molecular mechanism that may be useful for optimizing therapy

Maria V. Burkaltseva

I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia

Lazareva A.V.

National Medical Research Center for Children’s Health, Moscow, Russia

Pleteneva E.A.

I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia

Shaburova O.V.

I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia

Krylov S.V.

I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia

Mikhailova N.A.

I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia

Poddubikov A.V.

I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia

Lazarev S.A.

I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia

Zverev V.V.

I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia

Krylov V.N.

I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia

  • 1. Mariani-Kurkdjian P., Bingen E. Pathogenic bacteria in cystic fibrosis. Arch Pediatr. 2003;10(Suppl. 2):342s-346s. DOI: 10.1016/S0929-693X(03)90050-9
  • 2. Navon-Venezia S., Ben-Ami R., Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis. 2005;18:306313. DOI: 10.1097/01.qco.0000171920.44809.f0
  • 3. Tan K., Conway S.P., Brownlee K.G., Etherington C., Peckham D.G. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol. 2002;34:101-104. DOI: 10.1002/ppul.10143
  • 4. Van Daele S., Verhelst R., Claeys G., Verschraegen G., Franckx H., Van Simaey L., et al. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center. J Clin Microbiol. 2005;43:2998-3002. DOI: 10.1128/JCM.43.6.2998-3002.2005
  • 5. Ronne Hansen C., Pressler T., Hoiby N., Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients: a retrospective case-control study. J Cyst Fibros. 2006;5:245-251. DOI: 10.1016/j.jcf.2006.04.002
  • 6. De Baets F., Schelstraete P., Van Daele S., Haerynck F., Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros. 2007;6:75-78. DOI: 10.1016/j.jcf.2006.05.011
  • 7. Stobbelaar K., Van Hoorenbeeck K., Lequesne M., De Dooy J., Ho E., Vlieghe E., et al. Sepsis caused by Achromobacter xylosoxidans in a child with cystic fibrosis and severe lung disease. Am J Case Rep. 2016;17:562-566. DOI: 10.12659/AJCR.896577
  • 8. Talbot N.P., Flight W.G. Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis. Paediatr Respir Rev. 2016;(20 Suppl.):27-29. DOI: 10.1016/j.prrv.2016.06.011
  • 9. Cools P., Ho E., Vranckx K., Wurth B., Franckx H., Ievenet G., et al. Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature. BMC Microbiol. 2016;24:16(1):122. DOI: 10.1186/s12866-016-0736-1
  • 10. Shabalova L.A., Kapranov N.I., Krylov V.N. Susceptibility of Pseudomonas aeruginosa in patients with CF to P. aeruginosa bacteriophage. Proceedings of 6th Annual North American Cystic Fibrosis Conference, Washington D.C., USA, October 15-18, 1992; p. 295.
  • 11. Krylov V., Shaburova O., Pleteneva E., Bourkaltseva M., Krylov S., Kaplan A., et al. Modular approach to select bacteriophages targeting Pseudomonas aeruginosa for their application to children suffering with cystic fibrosis. Front Microbiol. 2016;7:1631. DOI: 10.3389/fmicb.2016.01631
  • 12. Hoyle N., Zhvaniya P., Balarjishvili N., Bolkvadze D., Nadareishvili L., Nizharadze D., et al. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Res Microbiol. 2018;169(9):540542. DOI: 10.1016/j.resmic.2018.05.001
  • 13. Alemayehu D., Casey P.G., McAuliffe O., Guinane C.M., Martin J.G., Shanahan F., et al. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio. 2012;3(2):e0002912. DOI: 10.1128/mBio.00029-12
  • 14. Waters E.M., Neill D.R., Kaman B., Sahota J.S., Clokie M.R., Winstanley C., et al. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax. 2017;72(7):666-667. DOI: 10.1136/thoraxjnl-2016-209265
  • 15. Firmida M.C., Marques E.A., Leao R.S., Vicente Pereira R.H., Rodrigues E.R., Albano R.M., et al. Achromobacter xylosoxidans infection in cystic fibrosis siblings with different outcomes: Case reports. Respir Med Case Rep. 2017;20:98-103. DOI: 10.1016/j.rmcr.2017.01.005
Views
0 Abstract
0 PDF
0 Crossref citations
Shared